Repligen Corporation $RGEN Position Increased by Bamco Inc. NY

Bamco Inc. NY raised its position in Repligen Corporation (NASDAQ:RGEN) by 42.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 544,779 shares of the biotechnology company’s stock after purchasing an additional 163,101 shares during the quarter. Bamco Inc. NY owned approximately 0.97% of Repligen worth $89,267,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of RGEN. NewEdge Wealth LLC lifted its holdings in shares of Repligen by 5.3% during the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 75 shares during the last quarter. UMB Bank n.a. increased its holdings in Repligen by 13.8% in the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after buying an additional 92 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Repligen by 0.3% in the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after buying an additional 100 shares during the last quarter. Coldstream Capital Management Inc. raised its position in Repligen by 5.3% during the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 101 shares in the last quarter. Finally, Itau Unibanco Holding S.A. raised its position in Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 104 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on RGEN shares. Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target on the stock. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the company a “buy” rating in a research note on Friday, April 17th. Canaccord Genuity Group decreased their price objective on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average price target of $164.64.

Repligen Price Performance

Shares of Repligen stock opened at $133.55 on Thursday. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The firm has a fifty day simple moving average of $121.10 and a 200-day simple moving average of $136.86. The stock has a market capitalization of $7.53 billion, a price-to-earnings ratio of 148.39, a PEG ratio of 2.54 and a beta of 1.09. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $175.77.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. Repligen’s revenue was up 14.8% compared to the same quarter last year. During the same period last year, the business posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, sell-side analysts expect that Repligen Corporation will post 1.99 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.